Life (May 2023)

Should We Change the Target of Therapy in Pulmonary Hypertension?

  • Panagiotis Karyofyllis,
  • Eftychia Demerouti,
  • Pavlos Habibis,
  • Styliani Apostolopoulou,
  • Eleftheria-Garyfallia Tsetika,
  • Dimitrios Tsiapras

DOI
https://doi.org/10.3390/life13051202
Journal volume & issue
Vol. 13, no. 5
p. 1202

Abstract

Read online

Despite the evolution of drug therapy in pulmonary arterial hypertension and the more aggressive treatment approach according to the guidelines, patients continue to have unacceptable mortality rates. Furthermore, specific drug therapy alone in chronic thromboembolic pulmonary hypertension also does not seem to have any beneficial impact on survival. As the function of the right ventricle (RV) determines the prognosis of patients with pulmonary hypertension, the treatment strategy should focus on modifying factors involved in RV dysfunction. Although some previous reports demonstrated that the survival of patients with pulmonary hypertension was associated with mPAP, nevertheless, mPAP is still not considered as a target of therapy. There are many examples of effective mPAP lowering with early and aggressive drug therapy in pulmonary arterial hypertension, or with interventions in chronic thromboembolic pulmonary hypertension. This effective mPAP reduction can lead to reverse RV remodeling, and thus, improvement in survival. In this article, the importance of mPAP lowering is stated, as well as why the change of our current strategy and considering mPAP reduction as the target of therapy could make pulmonary hypertension a chronic but not fatal disease.

Keywords